ICON Public (NASDAQ:ICLR) Releases Earnings Results, Beats Expectations By $0.01 EPS

ICON Public (NASDAQ:ICLR) released its quarterly earnings results on Wednesday. The medical research company reported $3.42 earnings per share for the quarter, topping analysts’ consensus estimates of $3.41 by $0.01, Zacks reports. ICON Public had a return on equity of 11.91% and a net margin of 9.00%.

ICON Public Trading Up 1.4 %

ICON Public stock traded up $2.67 during midday trading on Wednesday, reaching $191.32. The stock had a trading volume of 1,456,565 shares, compared to its average volume of 951,855. ICON Public has a twelve month low of $181.51 and a twelve month high of $347.72. The stock has a market capitalization of $15.78 billion, a PE ratio of 21.33, a price-to-earnings-growth ratio of 1.70 and a beta of 1.19. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.34 and a current ratio of 1.34. The stock’s 50-day simple moving average is $203.63 and its 200 day simple moving average is $246.83.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on ICLR. The Goldman Sachs Group lowered their target price on ICON Public from $370.00 to $280.00 and set a “buy” rating on the stock in a report on Friday, October 25th. TD Cowen lowered their target price on ICON Public from $369.00 to $285.00 and set a “buy” rating on the stock in a report on Friday, October 25th. Royal Bank of Canada reiterated an “outperform” rating and set a $263.00 target price on shares of ICON Public in a report on Wednesday, January 15th. Leerink Partners reiterated an “outperform” rating and set a $255.00 target price (down previously from $270.00) on shares of ICON Public in a report on Tuesday, November 19th. Finally, William Blair reaffirmed an “outperform” rating on shares of ICON Public in a research report on Tuesday, January 14th. Four equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, ICON Public currently has a consensus rating of “Moderate Buy” and a consensus target price of $283.92.

ICON Public Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.